Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effects of a Dietary Supplement on Lipoprotein Lipids and Inflammatory Markers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03118583
Recruitment Status : Completed
First Posted : April 18, 2017
Last Update Posted : May 15, 2018
Sponsor:
Information provided by (Responsible Party):
Midwest Center for Metabolic and Cardiovascular Research

Brief Summary:
The goal of this study is to assess the effects of a dietary supplement on fasting lipoprotein lipids and a marker of inflammation in men and women with levels of low-density lipoprotein cholesterol above desirable levels.

Condition or disease Intervention/treatment Phase
Healthy Volunteers Dietary Supplement: 300 mg/day of dietary supplement containing carrageenan Not Applicable

Detailed Description:

Carrageenan is a naturally occurring plant polysaccharide extracted from edible seaweeds that is widely used in food and beverage products, with a history of use dating back hundreds of years. It is an FDA-approved food additive in the U.S. and has regulatory approval for use as a food ingredient in Europe, Asia, and Latin America.

An earlier clinical trial conducted by the Russian Academy of Sciences demonstrated that consumption of 250 mg/day of carrageenan in capsules, for 28 days, lowered low-density lipoprotein cholesterol (LDL-C) by 34%. In that study, carrageenan consumption also resulted in statistically significant decreases in important biomarkers of chronic inflammation: leukocytes by 16%, fibrinogen by 9%, and C-reactive protein (CRP) by 13%. Another clinical trial conducted by the University of the Philippines showed that carrageenan added to foods led to statistically significant decreases in total cholesterol (total-C) and triglycerides (TG), elevated levels of which are also linked to cardiovascular disease. That study showed that carrageenan consumption led to a 33% reduction in total-C and a 32% reduction in TG.

This is a pilot, open-label, 4 week trial with two screening visits, one baseline visit and two test visits. Subjects will consume 300 mg/day of a proprietary dietary capsule containing carrageenan, with a meal at a consistent time each day, starting at the baseline visit. Fasting blood samples will be collected for lipid profile (total-C, LDL-C, high-density lipoprotein cholesterol [HDL-C], and TG), and high-sensitivity CRP (hs-CRP) measurements at the second screening visit, baseline and the two test visits. Additionally, blood will be drawn for a comprehensive metabolic panel and complete blood count at the second screening and the last test visit only. Assessments of vital signs, body weight, evaluation of inclusion and exclusion criteria, concomitant medication/supplement use, and adverse events will be performed throughout the study. Written study instructions will be provided to the subjects including instructions about fasting, maintenance of adequate hydration, and refraining from vigorous physical activity, alcohol consumption, and tobacco products prior to and during the subsequent visit. At the end of the 4 week test period, subjects will return study product and compliance will be assessed.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 12 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Supportive Care
Official Title: An Open-label, Pilot Trial to Assess the Effects of a Dietary Supplement on Fasting Lipoprotein Lipids and a Marker of Inflammation in Men and Women With Above-desirable Levels of Low-density Lipoprotein Cholesterol
Actual Study Start Date : March 15, 2017
Actual Primary Completion Date : December 31, 2017
Actual Study Completion Date : January 31, 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Dietary supplement with carrageenan
300 mg/day of dietary supplement containing carrageenan
Dietary Supplement: 300 mg/day of dietary supplement containing carrageenan
300 mg/day of dietary supplement containing carrageenan.




Primary Outcome Measures :
  1. LDL-C [ Time Frame: Up to 28 days ]
    Percent change in LDL-C from baseline (average of values at days -7 and 0) to end of treatment (average of values at days 21 and 28)


Secondary Outcome Measures :
  1. Total-C [ Time Frame: Up to 28 days ]
    Percent change in total-C from baseline (average of values at days -7 and 0) to end of treatment (average of values at days 21 and 28)

  2. HDL-C [ Time Frame: Upto 28 days ]
    Percent change in HDL-C from baseline (average of values at days -7 and 0) to end of treatment (average of values at days 21 and 28)

  3. Total-C/HDL-C [ Time Frame: Up to 28 days ]
    Percent change in the ratio of total-C/HDL-C from baseline (average of values at days -7 and 0) to end of treatment (average of values at days 21 and 28)

  4. Non-high-density lipoprotein cholesterol (non-HDL-C) [ Time Frame: Upto 28 days ]
    Percent change in non-HDL-C (calculated as total-C minus HDL-C) from baseline (average of values at days -7 and 0) to end of treatment (average of values at days 21 and 28)

  5. Triglycerides (TG) [ Time Frame: Up to 28 days ]
    Percent change in TG from baseline (average of values at days -7 and 0) to end of treatment (average of values at days 21 and 28)

  6. hs-CRP [ Time Frame: Up to 28 days ]
    Change in hs-CRP from baseline (average of values at days -7 and 0) to end of treatment (average of values at days 21 and 28)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   25 Years to 69 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Body mass index 18.5-34.9 kg/m2
  2. Judged to be in good health on basis of medical history and screening laboratory tests
  3. Fasting LDL-C ≥115 mg/dL and <190 mg/dL

Exclusion Criteria:

  1. Abnormal laboratory test results of clinical significance (e.g., TG ≥400 mg/dL, blood glucose ≥126 mg/dL, fasting creatinine ≥1.5 mg/dL, alanine aminotransferase or aspartate aminotransferase ≥1.5X the upper limit of normal)
  2. Atherosclerotic cardiovascular disease or other evidence of atherosclerotic cardiovascular disease (myocardial infarction or other acute coronary syndrome, coronary or other revascularization procedure, transient ischemic attack, ischemic stroke, atherosclerotic peripheral arterial disease or other documented atherosclerotic diseases)
  3. Recent major trauma or surgical event
  4. History or presence of clinically important pulmonary, endocrine, hepatic, renal, hematologic, immunologic, dermatologic, neurologic, psychiatric, or biliary disorders
  5. History or current gastrointestinal disorder with the potential to disrupt normal digestion and absorption
  6. Known allergy, sensitivity, or intolerance to any ingredients in the study product
  7. Uncontrolled hypertension
  8. Recent history of cancer (except non-melanoma skin cancer)
  9. Recent weight change ≥4.5 kg
  10. History of diagnosed eating disorder
  11. Extreme dietary habits
  12. Current or recent history of, or strong potential for, drug or alcohol abuse
  13. Recent use of medications intended to alter the lipid profile, (e.g., statins, bile acid sequestrants, cholesterol absorption inhibitor, fibrates, niacin [drug form] or omega-3 fatty acid drugs), weight-loss drugs or programs, systemic corticosteroids, anticoagulants, or unstable use of any antihypertensive medication
  14. Recent use of foods or dietary supplements with potential to influence lipid metabolism (e.g., omega-3 fatty acid supplements or fortified foods, sterol/stanol products, red rice yeast supplements, garlic supplements, soy isoflavone supplements, niacin or its analogues at doses >400 mg/d) and viscous dietary fiber supplements (e.g., psyllium, beta-glucan, methylceullylose and/or carrageenan)
  15. Recent use of antibiotics
  16. Pregnant, planning to be pregnant during the study period or lactating females or women of childbearing potential unwilling to commit to use of a medically approved form of contraception

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03118583


Locations
Layout table for location information
United States, Florida
MB Clinical Research
Boca Raton, Florida, United States, 33487
Sponsors and Collaborators
Midwest Center for Metabolic and Cardiovascular Research
Investigators
Layout table for investigator information
Study Director: Kevin C Maki, PhD MB Clinical Research and Consulting LLC
Layout table for additonal information
Responsible Party: Midwest Center for Metabolic and Cardiovascular Research
ClinicalTrials.gov Identifier: NCT03118583    
Other Study ID Numbers: MB-1608
First Posted: April 18, 2017    Key Record Dates
Last Update Posted: May 15, 2018
Last Verified: May 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No